AVITA Medical, Inc. (RCEL)

NASDAQ: RCEL · IEX Real-Time Price · USD
13.58
+0.05 (0.37%)
Mar 29, 2023, 4:00 PM EDT - Market closed
0.37%
Market Cap 343.52M
Revenue (ttm) 25.11M
Net Income (ttm) -17.79M
Shares Out 25.30M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,418
Open 13.52
Previous Close 13.53
Day's Range 13.51 - 13.83
52-Week Range 4.41 - 14.75
Beta 0.97
Analysts Buy
Price Target 19.28 (+41.97%)
Earnings Date Feb 23, 2023

About RCEL

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professional... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Mr. James M. Corbett
Employees 116
Stock Exchange NASDAQ
Ticker Symbol RCEL
Full Company Profile

Financial Performance

In 2022, AVITA Medical's revenue was 37.64 million, an increase of 8.73% compared to the previous year's 34.62 million. Losses were -26.67 million, 6.06% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $19.28, which is an increase of 41.97% from the latest price.

Price Target
$19.28
(41.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AVITA Medical Appoints New Non-Executive Member to the Board of Directors

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

6 days ago - GlobeNewsWire

What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

1 week ago - Zacks Investment Research

How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%

The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...

2 weeks ago - Zacks Investment Research

AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference

VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

3 weeks ago - GlobeNewsWire

Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

1 month ago - Zacks Investment Research

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and c...

1 month ago - GlobeNewsWire

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

1 month ago - GlobeNewsWire

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?

Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...

2 months ago - Zacks Investment Research

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call

VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading th...

2 months ago - GlobeNewsWire

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

VALENCIA, Calif., and MELBOURNE, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

3 months ago - GlobeNewsWire

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commerc...

3 months ago - GlobeNewsWire

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

3 months ago - GlobeNewsWire

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

4 months ago - GlobeNewsWire

AVITA Medical® to Host Investor Webinar Briefing

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

4 months ago - GlobeNewsWire

Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable...

4 months ago - Zacks Investment Research

AVITA Medical Reports Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and c...

4 months ago - GlobeNewsWire

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

5 months ago - GlobeNewsWire

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

5 months ago - GlobeNewsWire

AVITA Medical to Announce Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

5 months ago - GlobeNewsWire

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

6 months ago - GlobeNewsWire

Investor Webinar Briefing (RCEL, AVH)

Valencia, California and Melbourne, Australia--(Newsfile Corp. - September 19, 2022) - AVITA Medical, Inc. (NASDAQ: RCEL) (ASX: AVH), a regenerative medicine company leading the development and commer...

6 months ago - Newsfile Corp

Investor Webinar Briefing

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

7 months ago - GlobeNewsWire

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commer...

7 months ago - GlobeNewsWire

RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting

Two presentations will highlight data utilizing the RECELL platform for repigmentation Two presentations will highlight data utilizing the RECELL platform for repigmentation

8 months ago - GlobeNewsWire

AVITA Medical Reports Second Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commer...

8 months ago - GlobeNewsWire